ABRAVO TOPICAL EMULSION- dressing, wound, drug    
Aletris Pharmaceuticals, LLC

----------

Abravo Topical Emulsion

TOPICAL EMULSION

Rx Only

Abravo is a water-based, non-sterile emulsion formulated for the dressing and management of superficial wounds, minor abrasions, dermal ulcers, donor sites, 1st and 2nd degree burns, including sunburns, and radiation dermatitis. When applied properly to a wound, Abravo provides an optimum moist environment for the healing process and isolates the wound from harmful germs and other external contamination.

Abravo is indicated for use in:

Abravo is contraindicated for use on bleeding wounds, skin rashes related to food or medicine allergies, and when an allergy to one of the ingredients is known.

Caution:

Abravo is for topical use only as directed by a healthcare professional.

Wounds, Abrasions, Full Thickness Wounds, Dermal Graft Site Management and Donor Site Management

  • Wash the affected area(s) with saline, clean water, or a suitable wound cleanser.
  • Apply Abravo on and around the affected area(s) in thick layers 1/4to 1/2 inch thick.
  • If applying gauze dressing, moisten the dressing lightly before application.
  • Reapply Abravo as described above every 24 to 48 hours or as directed until the wound or lesion has healed fully.
  • For donor site management, apply Abravo after skin removal and cover with a moist dressing. Reapply as directed.
  • For dermal graft site management, apply Abravo to the graft site only after the graft has taken successfully. Abravo can be washed away with a saline solution or clean water without causing damage to the newly formed tissues.

1st and 2nd Degree Burns, Including Sunburns

  • Before application of Abravo to burns, take precaution in removing any clothing in the affected area(s).
  • Apply Abravo as soon as possible on and around the affected area(s), in a thick 1/4 to 1/2 inch layer until the skin no longer absorbs the product. A white waxy residue may remain. If pain from the burn persists, apply thinner layers of Atopavo until the pain has ceased.
  • Continue to apply Abravo until the affected areas(s) has healed completely.
  • Application of Abravo to the affected area(s) should continue during any subsequent physical therapy treatments.

Radiation Dermatitis

  • Apply a generous amount of Abravo three times per day, seven days a week to the treated area(s), gently massaging the area(s) until Abravo is completely absorbed.
  • Abravo may be applied as indicated by the treating physician (see WARNINGS).
  • Continue to apply Abravoas described above until the skin has fully recovered.
  • Do not interrupt applications during the course of radiation therapy, even for one day.
  • Do not apply Abravo 4 hours prior to a radiation session.

Abravo contains purified water, liquid paraffin, ethylene glycol monostearate, stearic acid, propylene glycol, paraffin wax, squalane, avocado oil, trolamine/sodium alginate, triethanolamine, cetyl palmitate, methylparaben (sodium salt), sorbic acid (potassium salt), propylparaben (sodium salt), and fragrance.

Abravo is supplied in a 45-gram tube (60010-89071).
Store at room temperature, do not freeze.
Rx ONLY - Prescription Medical Device: Federal Law restricts this device to sale by or on the order of a physician (or properly licensed practitioner).

Manufactured for:
Aletris Pharmaceuticals, LLC.
1636 Popps Ferry Rd., Suite 218
Biloxi, MS 39532-2280
(228) 207-8112
www.aletrispharma.com

Call your doctor for medJcal advice about the side effects.
You may report side effects to FDA at 1-800-fDA-1088.

container image

carton image

ABRAVO TOPICAL EMULSION 
dressing, wound, drug
Product Information
Product TypePRESCRIPTION MEDICAL DEVICEItem Code (Source)GS1:86001089071
Packaging
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1GS1:8600108907145 g in 1 TUBE; Type 0: Not a Combination Product
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
premarket notificationK09287810/28/2023
Labeler - Aletris Pharmaceuticals, LLC (118956541)

Revised: 11/2023
Document Id: ecb8a516-d15a-42c3-ba0c-4fb9aa20653d
Set id: 3fa23fba-bef2-478c-adf1-fcb8b2d331be
Version: 1
Effective Time: 20231107
 
Aletris Pharmaceuticals, LLC